A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer

PURPOSE. Nintedanib enhances the activity of chemotherapy in metastatic NSCLC. In this phase I/II study, we assessed safety and efficacy of nintedanib plus neoadjuvant chemotherapy, using major pathologic response (MPR) as primary endpoint. EXPERIMENTAL DESIGN: Eligible patients had stage IB (≥4 cm)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Cascone, Tina, Sepesi, Boris, Lin, Heather Y., Kalhor, Neda, Parra, Edwin R., Jiang, Mei, Godoy, Myrna C. B., Zhang, Jianjun, Fossella, Frank V., Tsao, Anne, Lam, Vincent K., Lu, Charles, Mott, Frank E., Simon, George, Antonoff, Mara B., Mehran, Reza J., Rice, David C., Behrens, Carmen, Weissferdt, Annikka, Moran, Cesar, Vaporciyan, Ara A., Lee, J. Jack, Swisher, Stephen G., Gibbons, Don L., Wistuba, Ignacio I., William, William N., Heymach, John V.
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446232/
https://ncbi.nlm.nih.gov/pubmed/32193228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-4180
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars